Every 8-K that Thermo Fisher Scientific Inc. (TMO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMO filings page.
Thermo Fisher Scientific reported second quarter 2026 results, with revenue of $11.99 billion, up 10% including 5% organic growth. GAAP diluted EPS was $4.68, up 9%, and adjusted EPS was $6.03, up 13%. GAAP operating income reached $2.09 billion with a 17.4% margin, while adjusted operating income was $2.73 billion with a 22.8% margin. Free cash flow for the quarter was $1,678 million.
Management highlighted stronger end-market demand and several strategic initiatives, including next-generation Orbitrap mass spectrometry platforms, the Applied Biosystems PowerFlex Thermal Cycler, and a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts. The company announced a divestiture of its microbiology business and repurchased $1.0 billion of stock in the quarter. For the first half of 2026, revenue was $22,999 million with 8% growth and organic growth of 3%; GAAP diluted EPS was $9.10 and adjusted EPS was $11.47. Updated 2026 guidance will be discussed on the earnings call.
Thermo Fisher Scientific Inc. reported the results of shareholder voting from its May 20, 2026 annual meeting. All nominated directors were elected, each receiving substantially more votes "For" than "Against." For example, Debora L. Spar received 314,426,121 votes for and 311,821 against.
A key outcome was that a non-binding, advisory proposal on the compensation of the company’s named executive officers was not approved, with 99,928,178 votes for and 214,525,673 against. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 296,866,709 votes for and 36,064,900 against.
Thermo Fisher Scientific Inc. reported solid first quarter 2026 results, with revenue up 6% to $11.01 billion and organic revenue growth of 1%. GAAP diluted EPS rose 11% to $4.43, while adjusted EPS increased 6% to $5.44, reflecting higher operating income and slightly improved GAAP operating margin of 16.9%.
Adjusted operating income grew to $2.40 billion with an adjusted operating margin of 21.8%. Free cash flow more than doubled to $825 million. The company completed the acquisition of Clario, repurchased $3.0 billion of stock, increased its dividend by 10%, and continued launching new products and strategic collaborations.
Thermo Fisher Scientific has completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earn-out and other performance-based payments. The deal also includes a further $125 million payment due in January 2027 and up to $400 million of earn-out payments tied to Clario’s results in 2026 and 2027.
Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment, enhancing its clinical research data capabilities. Thermo Fisher expects the transaction to generate a double-digit internal rate of return, be accretive to adjusted operating margin, add $0.45 of adjusted EPS in the first year after close, and deliver about $175 million of adjusted operating income synergies by year five.
Thermo Fisher Scientific Inc. issued four new series of senior unsecured notes totaling $4.8 billion to raise long-term debt capital. The company sold $1.0 billion of 4.215% Notes due 2031, $750 million of 4.550% Notes due 2033, $1.3 billion of 4.902% Notes due 2036 and $750 million of 5.546% Notes due 2046 in a public offering.
Thermo Fisher expects net proceeds of approximately $3.76 billion after underwriting discounts and expenses. It intends to use these funds primarily to pay a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc., with any remainder available for general corporate purposes or temporary short-term investments.
The notes include standard optional redemption features before and after defined par call dates, a change-of-control repurchase right at 101% of principal upon specified rating downgrades, and customary covenants limiting secured debt on principal properties, sale-leaseback transactions, and certain mergers or asset sales.
Thermo Fisher Scientific Inc. furnished an update on its business by announcing financial results for the fiscal quarter and full year ended December 31, 2025. The company released these results through a press release dated January 29, 2026.
The press release containing the detailed quarterly and annual financial information is provided as Exhibit 99.1. This information is treated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, which limits how it is incorporated into other regulatory documents.
Thermo Fisher Scientific Inc. reported upcoming leadership changes following the planned departures of two senior executives. Executive Vice President and Chief Operating Officer Michel Lagarde, who has held the COO role since 2021, will leave the company on March 31, 2026. Executive Vice President Frederick M. Lowery, in that role since 2024, will depart on February 28, 2026.
Effective March 1, 2026, the company will update its organizational structure. Marc N. Casper will serve as Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted to President and Chief Operating Officer, while Michael Shafer, also an Executive Vice President, will move into an expanded role reporting directly to the Chief Executive Officer. These changes outline Thermo Fisher’s succession and leadership realignment plan at the top of the organization.
Thermo Fisher Scientific Inc., through its finance subsidiary Thermo Fisher Scientific (Finance I) B.V., issued €1,000,000,000 of Floating Rate Senior Notes due 2027 and €1,100,000,000 of 3.628% Senior Notes due 2035 in a public offering, fully and unconditionally guaranteed on a senior unsecured basis by the company. The notes were issued under an existing indenture and a new supplemental indenture, with quarterly interest on the floating rate notes and annual interest on the fixed rate notes.
The 2035 fixed rate notes are redeemable before a September 1, 2035 par call date at a make-whole redemption price and at par thereafter, and both series include a change-of-control put at 101% of principal plus accrued interest if the company undergoes a qualifying change of control with concurrent ratings downgrades. The company expects net proceeds of approximately €2.09 billion and intends to use them for general corporate purposes, including potential acquisitions, debt repayment or refinancing, working capital, capital spending, and share repurchases, or for temporary investment in short-term liquid instruments.
Thermo Fisher Scientific (TMO) announced a definitive agreement to acquire Clario Holdings for approximately $8.875 billion in cash at closing, plus $125 million in deferred consideration and up to $400 million in contingent consideration. The transaction is expected to close by the middle of 2026, subject to customary closing conditions and regulatory approvals.
This deal adds a significant clinical research and data-focused asset to Thermo Fisher’s portfolio. The consideration structure mixes upfront cash with deferred and contingent payments, aligning part of the price to post‑closing outcomes. The company noted typical regulatory and integration risks and referenced risk factors in its latest periodic reports.
Thermo Fisher Scientific (TMO) furnished an update on its financial results by filing an Item 2.02 Form 8‑K. The company announced results for the fiscal quarter ended September 27, 2025 and provided the full details in a press release furnished as Exhibit 99.1.
The information is furnished and not deemed filed under Section 18 of the Exchange Act. Additional materials include the Cover Page Interactive Data File (Exhibit 104).
Thermo Fisher Scientific sold a new series of notes under an underwriting agreement entered on September 30, 2025 and reported the related event on October 7, 2025. The company expects net proceeds of approximately $2.48 billion after underwriting discounts and offering expenses.
The company intends to use the net proceeds for general corporate purposes, which may include acquisitions, repayment and refinancing of debt, working capital, capital expenditures, repurchases of equity securities, or temporary investment in short-term liquid instruments. The Underwriting Agreement is filed as Exhibit 1.1; a Twenty-Ninth Supplemental Indenture is filed as Exhibit 4.2, and a legal opinion and consent from its counsel are filed as Exhibit 5.1/23.1.
Thermo Fisher Scientific Inc. has completed its acquisition of Solventum Corporation’s purification and filtration business. The company announced the closing in a press release dated September 2, 2025, following the earliest event date of September 1, 2025.
The acquired operations focus on purification and filtration technologies, which fit within Thermo Fisher’s broader scientific and laboratory solutions portfolio. Details such as purchase price, financing, and expected financial impact are not included in this summary document but are referenced in the attached press release.